1 / 34

Patient Medication Acceptability and Treatment Options:

Learn about Ibogaine, Methadone, and Buprenorphine as treatments for opioid addiction, their history, and patient experiences. Understand the advantages and challenges of each medication.

jdemarest
Download Presentation

Patient Medication Acceptability and Treatment Options:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patient Medication Acceptability and Treatment Options: Ibogaine Methadone Buprenorphine Howard S. Lotsof DORA WEINER FOUNDATION

  2. Background: Drug Control • 1906 Pure Food and Drug Act • 1914 Harrison Narcotic Act • 1970 Controlled Substances Act

  3. Background: Methadone • 1937 synthesized by Max Bockmühl and Gustav Ehrhart, I.G. Farbenindustries. Patent issued 1941 • 1950 use in treatment of opioid abstinence syndrome established in US • 1964 use in opioid maintenance therapy

  4. Methadone molecule

  5. Methadone powder

  6. Methadone diskets

  7. Methadone liquid

  8. Background: Buprenorphine • 1965 synthesized by KW Bentley at Rickitt & sons, UK. • 1975 - 1978 DR Jazinski et al. Indicate utility in treating opiate addiction • 1977 - 2003 John Lewis champions analgesic and antiaddictive development • 2000 Drug Addiction Treatment Act authorizes use in opioid maintenance therapy • 2002 FDA approves that use to Reckitt Benckiser

  9. Buprenorphine molecule

  10. Buprenorphine productsmanufacturer, Reckitt Benckiser will not make current product photographs available

  11. Background: IbogaineAn experimental medication • Botanical source Tabernanthe iboga. Used for 100s of years in African medicine and religion • 1901 ibogaine isolated by Dybowski and Landrin • 1958 molecular structure determined Bartlett et al. • 1962 Lotsof discovers Antiaddictive effects • 1993 - 2003 Mash & Glick develop second generation ibogaine-like drugs

  12. Ibogaine molecule

  13. NoribogaineLiver transforms ibogaine into noribogaine

  14. 18-methoxycoronaridine molecule18-MCSynthetic molecule

  15. Tabernanthe iboga shrub

  16. Roots bark contain ibogaine

  17. Pharmaceutical ibogaineexperimental medication

  18. Methadone NYC 1964 Doctors administer to drugs users Ibogaine NYC 1962 Drug users administer to drug users Discovery of antiaddctiveeffects Buprenorphine Lexington, KY 1975 Pharmaceutical industry/gov. Development

  19. Methadone The golden age of Dole and Nyswander 1966 - 1973

  20. Drs. Dole and Nyswander ca 1976

  21. Early generation methadone patients • The program was administered or controlled by doctors in a medical research environment even at the clinic level. • Nurses, counselors and patients believed in opioid maintenance therapy and collaborated to make it work. Patients and staff were a team. • There was no “us” and “them”. Patients were treated like any other medical patients.

  22. Early generation ibogaine patients A full collaboration between academic researchers, pharmaceutical developers and user self-help groups with mutual respect. Equal status between the parties. Users, doctors and drug developers worked together to define the ideal administration paradigm. There was no “us” and “them”. Patients were treated just like any other medical patients, except when they were treated like doctors.

  23. Later generation ibogaine patients Drug users are no longer involved as equal participants in ibogaine development. Drug users and self-help groups, no longer affiliated with medical academics or drug developers, lost a level of authority and control. Ibogaine patients are not dependent on clinic administered drugs. Ibogaine providers generally leave the field rather than control or abuse patients. This could change in the future.

  24. Later Generation Methadone PatientsWhat’s wrong with methadone today? Nothing is wrong with methadone. Almost something is wrong with many clinics that administer and provide it to patients. Medical decisions are often not made by medical doctors. Many clinics practice control of patients rather than providing them with ethical medical care.

  25. Buprenorphine patients Buprenorphine patients never shared an important role in the development of the drug. The manufacturer and the US government appear to desire that stigma associated with chemical dependence not be attached to buprenorphine. Whether this early generation or later generations of buphrenorphine patients are well treated by the medical community and society will have to be seen.

  26. Two important issues in chemical dependence treatment Stigma Discrimination

  27. Stigma Focuses attention on the victim

  28. Discrimination: Focuses attention on those who produce rejection and exclusion

  29. The ibogaine advantage Ibogaine removes the stigmatized condition.

  30. Why ibogaine is not available? Industry deems ibogaine not to be profitable. Government, industry and academia chose to place their interest in the development of opiate drugs with which they are familiar. 3. Ibogaine represents a new scientific paradigm to the understanding of addiction.

  31. Ibogaine availability proximate to United States St Kitts West Indies Vancouver, BC, Canada Rosarito, Baja, Mexico

  32. Ibogaine availability

  33. Ibogaine resources The Ibogaine Dossier An internet library http://www.ibogaine.org http://www.ibogaine.desk.nl

  34. Manual for Ibogaine TherapySecond Revision Release date Friday, May 9, 2003 http://www.ibogaine.org/manual.html

More Related